In advanced bioprocessing, achieving high titres in microbial production is celebrated. However, the ultimate measure of success lies in the net titre, which considers both efficiency and yield as the protein moves through and out of downstream processing (DSP).

Traditional bioprocessing methods prioritize optimizing expression systems for high titres using standard host cells like Chinese hamster ovary (CHO) or Pichia pastoris. While effective initially, these methods frequently fall short in net yield due to inefficiencies in DSP. Complex purification processes, increased costs and reduced efficiency often result from high initial titres.

Balancing impressive initial titres with the practical economic realities of purification and overall yield is a critical challenge faced by drug developers with clinical manufacturing aspirations. These limitations underscore the necessity for a comprehensive bioprocess optimization strategy integrating both upstream and downstream processes.

In this webinar, the speaker will share how an integrated approach maximizes net titre by combining high titre production with efficient DSP. This involves optimizing the genetic and metabolic pathways of host cells and refining downstream processes to minimize product loss. Techniques such as quantitative trait loci (QTL) technology and advanced synthetic biology enhance strain robustness, improving production, lowering production costs and enhancing yield. Compared to traditional methods, this integrated strategy ensures high titres translate into commercially viable and sustainable net yields.

Addressing DSP challenges upfront facilitates smooth scale-up from lab to current good manufacturing practice (CGMP) production. The speakers will briefly touch on how combining international excellence in Saccharomyces cerevisiae strain development, this integrated strategy and decades of experience in biomanufacturing creates a one-of-a-kind solution for next-generation drug developers looking to hit their bioprocessing milestones.

Read Less...

Register for this webinar today to understand how to maximize net titres in bioprocessing through an integrated approach that combines high titre production with efficient downstream processing.

Keywords:

Speakers

Professor Ed Louis, PhD, R&D Director, Phenotypeca Limited

Ed Louis is a Professor of Genetics, who has over 35 years of experience in yeast genetics and genomics, particularly in genetic and phenotypic diversity. Having concluded his life in academia, Ed joined Phenotypeca to harness his knowledge into commercial applications. Ed currently oversees the technical output of the company, ensuring quality is met and timelines are kept.

Message Presenter

Johnny Cordiner, CEO, Phenotypeca Limited

Johnny Cordiner brings over 20 years of C-suite life sciences leadership to Phenotypeca. As a CEO, CFO and Commercial Director, Johnny has specialized in technologies focused on the complexity of biology. His experience includes translation of research into product development, commercial implementation, strategy as well as IPO, M&A and patent strategy.

Message Presenter

Who Should Attend?

This webinar will appeal to those with the following titles or:

Developers of peptides, vaccines, VHH or biosimilars
Developers of large-volume biologic therapeutics plus discovery programs
CEO/CTO/CSO/MD
Head of BD/R&D/Sales/Supply Chain/Innovation
Director of Operations/Product Development
Product Development Leaders

What You Will Learn

Attendees will learn about:

The pitfalls of overreliance on high titre compared to net titre
The reality of the limitations of existing market offerings and circumstances when this could have critical implications for projects
The importance of an integrated approach to mitigate pitfalls and maximize net titre
How custom strain development and CGMP biomanufacturing excellence can result in an attractive partnership for customers

Xtalks Partner

Cytovance®

Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation, such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well-integrated development services supporting the entire product lifecycle, including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical CMC activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.